Mural Oncology Set to Showcase Research at SITC Annual Meeting
Mural Oncology plc (NASDAQ: MURA), a pioneering company focused on immuno-oncology, is gearing up for a significant event—the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This important gathering will take place from November 6-10, 2024, in Houston, Texas. Mural Oncology is excited to announce they will be presenting key insights into their innovative therapies aimed at addressing critical cancer treatment challenges.
Presentations Highlighting Cutting-Edge Research
At the event, Mural Oncology plans to showcase three impactful poster presentations. The first presentation will delve into pharmacodynamic data derived from the phase 1/2 ARTISTRY-3 study, which explores less frequent dosing of nemvaleukin, their engineered interleukin-2 therapy. This research is essential, as it aims to provide deeper insight into the tumor microenvironment and how treatment with nemvaleukin can be optimized.
Details of Upcoming Presentations
Here are the specific details about the presentations Mural Oncology will be sharing at the SITC:
Tumor Microenvironment Study
Title: Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Abstract Number: 217
Presentation Date: Friday, Nov. 8
IL-18 and IL-12 Research Findings
Title: Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Abstract Number: 1340
Presentation Date: Saturday, Nov. 9
Title: Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits
Abstract Number: 1300
Presentation Date: Saturday, Nov. 9
About Mural Oncology
Mural Oncology is utilizing its advanced protein engineering platform to create innovative immunotherapies for cancer. With an emphasis on developing cytokine therapies, the company aims to provide meaningful benefits to patients facing various types of cancer. Their lead candidate, nemvaleukin, is currently involved in trials for platinum-resistant ovarian cancer and mucosal melanoma, with results expected in the near future.
The Functionality of Nemvaleukin
Nemvaleukin is engineered to enhance the anti-tumor properties of the interleukin-2 (IL-2) pathway without the side effects commonly associated with traditional treatments. It specifically interacts with the intermediate-affinity IL-2 receptor, promoting the growth of CD8+ T cells and natural killer cells, essential for mounting effective immune responses against tumors, while minimizing the unwanted expansion of regulatory T cells.
Exploring IL-18 and IL-12 Programs
Mural Oncology is also making strides in its IL-18 program, which aims to overcome limitations posed by IL-18 binding protein, a decoy receptor that hinders the efficacy of native IL-18. Through innovative protein engineering techniques, they are working to enhance the stability and potency of IL-18.
Furthermore, the IL-12 program is equally crucial. By reformulating IL-12 into separate inactive components, Mural Oncology seeks to deliver powerful anti-cancer effects while avoiding systemic toxicity. This revolutionary approach could change how IL-12 therapies are administered and ultimately improve patient outcomes.
Contact Mural Oncology for Inquiries
If you have further questions or require more information about Mural Oncology and its programs, please reach out to:
Katie Sullivan
Email: katie.sullivan@muraloncology.com
Frequently Asked Questions
What is Mural Oncology known for?
Mural Oncology is recognized for developing innovative cytokine-based immunotherapies aimed at improving cancer treatment outcomes.
What will Mural Oncology present at the SITC meeting?
The company will present data from its ARTISTRY-3 study and findings on its IL-18 and IL-12 programs.
Why is nemvaleukin significant?
Nemvaleukin is engineered to enhance immune responses against tumors while minimizing adverse side effects, representing a promising treatment option for patients.
What is the purpose of the IL-18 program?
The IL-18 program aims to enhance the efficacy and durability of IL-18, making it more effective in stimulating immune responses against cancer.
How can I learn more about Mural Oncology?
Visit Mural Oncology's official website or contact them directly for additional information on their research and development initiatives.